We are live on ! Find out more
AP

Antipodes Partners Portfolio holdings

AUM $5.19B
1-Year Est. Return 36.17%
This Fund
S&P 500
This Quarter Est. Return
+3.7%
1 Year Est. Return
+36.17%
3 Year Est. Return
+104%
5 Year Est. Return
+169.34%
10 Year Est. Return
–
AUM
$3.19B
AUM Growth
+$315M
Cap. Flow
+$277M
Cap. Flow %
8.69%
Top 10 Hldgs %
51.51%
Holding
117
New
38
Increased
39
Reduced
22
Closed
14

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$131M
2
JD icon
JD.com
JD
+$62.6M
3
KEYS icon
Keysight
KEYS
+$51.1M
4
LEN icon
Lennar Class A
LEN
+$45.5M
5
MU icon
Micron Technology
MU
+$35.9M

Top Sells

Rank Stock Value
1
T icon
AT&T
T
+$63.9M
2
ORCL icon
Oracle
ORCL
+$38.4M
3
OXY icon
Occidental Petroleum
OXY
+$35.8M
4
QCOM icon
Qualcomm
QCOM
+$28.8M
5
BABA icon
Alibaba
BABA
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 17.87%
2 Technology 15.34%
3 Materials 14.43%
4 Financials 12.5%
5 Consumer Discretionary 11.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYRG icon
76
MYR Group
MYRG
$5.15B
$81.3K ﹤0.01%
719
+101
+16% +$13.4K
ESTA icon
77
Establishment Labs
ESTA
$2.75B
$80.6K ﹤0.01%
+1,975
New +$73.6K
GPCR icon
78
Structure Therapeutics
GPCR
$3.52B
$73.5K ﹤0.01%
4,247
+3,213
+311% +$78.7K
RARE icon
79
Ultragenyx Pharmaceutical
RARE
$2.56B
$56.8K ﹤0.01%
+1,568
New +$65.2K
CERT icon
80
Certara
CERT
$1.21B
$53.9K ﹤0.01%
5,442
– –
LUMN icon
81
Lumen
LUMN
$6.76B
$44.6K ﹤0.01%
11,386
– –
GE icon
82
GE Aerospace
GE
$368B
$40.6K ﹤0.01%
203
+34
+20% +$6.69K
NTRA icon
83
Natera
NTRA
$38.6B
$40K ﹤0.01%
+283
New +$45.5K
ADSK icon
84
Autodesk
ADSK
$49.6B
$39.5K ﹤0.01%
151
+13
+9% +$3.7K
NUVL
85
DELISTED
Nuvalent
NUVL
$38.3K ﹤0.01%
+540
New +$42.2K
SDGR icon
86
Schrodinger
SDGR
$1.15B
$37.1K ﹤0.01%
+1,878
New +$42.3K
SPRY icon
87
ARS Pharmaceuticals
SPRY
$559M
$37K ﹤0.01%
+2,943
New +$35.4K
EXC icon
88
Exelon
EXC
$46.6B
$34.2K ﹤0.01%
+743
New +$31.1K
D icon
89
Dominion Energy
D
$61.3B
$33.9K ﹤0.01%
+604
New +$33.2K
SIBN icon
90
SI-BONE Inc
SIBN
$798M
$33.6K ﹤0.01%
+2,394
New +$38.6K
PRCT icon
91
Procept Biorobotics
PRCT
$1.02B
$29.5K ﹤0.01%
+507
New +$34.6K
GEV icon
92
GE Vernova
GEV
$262B
$24.1K ﹤0.01%
+79
New +$27.5K
LUMN icon
93
PUT
Lumen
LUMN
$6.76B
$23.7K ﹤0.01%
113
– –
IR icon
94
Ingersoll Rand
IR
$33B
$22K ﹤0.01%
275
-38
-12% -$3.31K
ORIC icon
95
Oric Pharmaceuticals
ORIC
$1.2B
$21.3K ﹤0.01%
+3,822
New +$33.4K
APGE icon
96
Apogee Therapeutics
APGE
$10.2B
$20.3K ﹤0.01%
+542
New +$21K
MASS icon
97
908 Devices
MASS
$313M
$19.6K ﹤0.01%
+4,382
New +$13K
JANX icon
98
Janux Therapeutics
JANX
$950M
$17.1K ﹤0.01%
+632
New +$23.8K
DAWN
99
DELISTED
Day One Biopharmaceuticals
DAWN
$16.2K ﹤0.01%
+2,043
New +$22K
ASHR icon
100
CALL
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
$1.55B
$15.6K ﹤0.01%
+15,550
New +$412K
1 2 3
4
5

Similar funds

MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
AUB
Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return
KACA
Kayne Anderson Capital Advisors Los Angeles, California $5.22B AUM 17.11% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
MIM
Merewether Investment Management Dallas, Texas $5.16B AUM 86.81% 1-Year Est. Return
AAI
Aequim Alternative Investments Mill Valley, California $5.16B AUM 9.8% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

Antipodes Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Antipodes Partners held 117 positions worth $3.19B, up 11% from $2.88B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Antipodes Partners deployed $277M of net new capital in Q1 2025, opening 38 new positions and adding to 39 existing holdings. Its largest new stake was Lennar Class A: 364,040 shares worth $41.8M.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 12% a quarter earlier, followed by Technology and Materials.

On the sell side, the largest reduction was AT&T, an estimated $63.9M trimmed.

  • Antipodes Partners's largest Q1 2025 buy was Lennar Class A: 364,040 shares worth $41.8M.
  • Antipodes Partners added most to HCA Healthcare in Q1 2025, an estimated $131M increase.
  • Antipodes Partners's biggest Q1 2025 reduction was AT&T, cutting an estimated $63.9M.
  • Antipodes Partners fully exited Frontier Communications in Q1 2025, selling an estimated $20.3M.
  • Antipodes Partners's ten largest holdings make up 52% of its $3.19B portfolio in Q1 2025.
  • Antipodes Partners opened 38 new positions and closed 14 in Q1 2025.
  • Antipodes Partners's portfolio value rose 11% quarter-over-quarter to $3.19B.

Based on Antipodes Partners's 13F filing for Q1 2025, filed 6 May 2025.